Investor News
--------------------------------------------------------------------------------
| NeuroSearch announces the date for its 2008 first half-year interim report |
| and related telephone conference
--------------------------------------------------------------------------------
| NeuroSearch's (NEUR.CO) interim report for the first half-year 2008 will be |
| on the agenda of a board meeting scheduled for 27 August 2008 and be |
| released immediately hereafter.
| On the same day, a telephone conference will be held at 3 pm Copenhagen time |
| (2 pm London time, 9 am New York time). Flemming Pedersen, CEO, Anita |
| Milland, Vice President, CFO and Hanne Leth Hillman, Vice President, |
| Director of IR & Corporate Communications, will present the interim report |
| and answer questions. The telephone conference will be conducted in English |
| and the telephone number is +44 (0)20 7162 0025. The corresponding |
| PowerPoint presentation will be available at www.neurosearch.com after the |
| release of the report.
|
--------------------------------------------------------------------------------
| Contact person: | Hanne Leth Hillman |
| | Vice President, Director of IR & Corporate Communications |
--------------------------------------------------------------------------------
| Telephone: | +45 4017 5103
--------------------------------------------------------------------------------
| NeuroSearch (NEUR.CO) is a Scandinavian biopharmaceutical company listed on |
| the OMX Nordic Exchange Copenhagen A/S. The company's core business covers |
| the development of novel drugs, based on a broad and well-established drug |
| discovery platform focusing on ion channels and CNS disorders. A substantial |
| share of its activities is partner financed through a broad alliance with |
| GlaxoSmithKline (GSK) and collaborations with, among others, Abbott and |
| Astellas. NeuroSearch's drug pipeline comprises 14 clinical (Phase I-III) |
| development programmes: ACR16 for Huntington's disease (Phase III), |
| tesofensine for obesity and in Type 2 diabetes (Phase III in preparation), |
| NS2359 for depression (Phase II) and ADHD (Phase II) in partnership with |
| GSK, ABT-894 for ADHD (Phase II) and pain (Phase II) in partnership with |
| Abbott, ACR16 for schizophrenia (Phase I) in partnership with Astellas, |
| ACR325 for Parkinson's disease (Phase II in preparation) and bipolar |
| disorder (Phase II in preparation), ABT-107 and ABT-560 for the treatment of |
| various CNS disorders - both (Phase I) in collaboration with Abbott, NSD-644 |
| for pain (Phase I) in partnership with GSK, ACR343 for Parkinson's disease |
| (Phase I) and NSD-788 for anxiety/depression (Phase I). In addition, |
| NeuroSearch has a broad portfolio of preclinical drug candidates and holds |
| equity interests in several biotech companies. |
--------------------------------------------------------------------------------
NeuroSearch announces the date for its 2008 first half-year interim report and related telephone conference
| Quelle: NTG Nordic Transport Group A/S
Anhänge
